To predict response to 18F-FDG PET/CT to chemotherapy in combination with Bevacizumab in patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Trial Profile

To predict response to 18F-FDG PET/CT to chemotherapy in combination with Bevacizumab in patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Erlotinib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 01 Aug 2017 Results published in the Journal of Nuclear Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top